Back to Journals » OncoTargets and Therapy » Volume 9

Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Authors Ji G, Hong L, Yang P

Received 10 April 2016

Accepted for publication 23 June 2016

Published 11 August 2016 Volume 2016:9 Pages 4989—4992

DOI https://doi.org/10.2147/OTT.S110235

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ru Chen

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Guanghui Ji,1 Liu Hong,2 Ping Yang3

1Department of Traditional Chinese Medicine, 2Department of Pathology, 3Department of Oncology, PLA Navy General Hospital, Beijing, People’s Republic of China


Abstract: Angiosarcoma is a rare and aggressive vascular malignancy with a poor prognosis. There is no standard chemotherapy regime for advanced angiosarcoma. Here, we report a case of advanced angiosarcoma that was successfully treated with apatinib, an oral tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). To our knowledge, this is the first case to report the successful use of apatinib for angiosarcoma. Furthermore, the administration of apatinib results in fewer toxic effects than traditional cytotoxic chemotherapy. Quantitative polymerase chain reaction analysis revealed high expression of VEGFR-2 mRNA, suggesting that apatinib leads to clinical response by inhibiting VEGFR-2 tyrosine kinase activity and that VEGFR-2 plays a crucial role for angiosarcoma. Apatinib may be an additional option for angiosarcoma especially for the aged and patients with poor performance status. Further prospective studies are required to optimize the use of apatinib in patients with angiosarcoma and to identify which patients will benefit from the agent.

Keywords: hemangiosarcoma, VEGFR-2, chemotherapy, angiogenesis inhibitor, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]